Joseph Aloi, MD
Endocrinology, Diabetes & Metabolism · Winston Salem, NCNPI 1194888958
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 81.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $11,575 and has fallen 95.0% since, to $573 in 2025.
Across 79 payments — averaging $219.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$14K
- Recordati_rare_diseases_inc.$2K
- Abbott$667
- Dexcom, Inc.$211
- Novo Nordisk$196
- Madrigal Pharmaceuticals$106
- plus $329 from 6 others
Across 157 payments — averaging $609.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Operations, Inc.$27K
- Neurocrine Biosciences, Inc.$22K
- Boehringer Ingelheim$17K
- Abbott$10K
- Boehringer Ingelheim Pharma GmbH & Co.kg$8K
- Medtronic$8K
- plus $3K from 2 others
What the payments were for
- Consulting fees$1,75410%
- Speaking & faculty fees$9,60055%
- Grants$570%
- Travel & lodging$2,31813%
- Food & beverage$3,49420%
- Education$1201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 51 | $14,129 |
| Recordati_rare_diseases_inc. | 2 | $1,704 |
| Abbott | 13 | $667 |
| Dexcom, Inc. | 3 | $211 |
| Novo Nordisk | 3 | $196 |
| Madrigal Pharmaceuticals | 1 | $106 |
| Boehringer Ingelheim | 1 | $102 |
| Shire North American Group Inc | 1 | $63 |
| Ascensia Diabetes Care US Inc. | 1 | $59 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| Corcept Therapeutics | 1 | $46 |
| Cequr Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$9,762
- OSILODROSTAT$1,704
- MINIMED 770G$1,628
- Minimed 630G$708
- MINIMED 780G$574
- FREESTYLE LIBRE 3$243
- DEXCOM G6 TRANSMITTER$125
- FreeStyle Lite system$120
- REZDIFFRA$106
- Minimed 530G$106
- JARDIANCE$102
How this compares
$17,342 in reported general payments places this provider in the 80th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $198,096 |
| MounjaroTirzepatide | 65 | $67,264 |
| JardianceEmpagliflozin | 51 | $60,008 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $34,344 |
| TrulicityDulaglutide | 33 | $31,755 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $23,251 |
| FarxigaDapagliflozin Propanediol | 11 | $16,781 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $16,003 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $14,938 |
| Gvoke Hypopen 2-PackGlucagon | 17 | $9,600 |
| Repatha SyringeEvolocumab | 12 | $7,639 |
| SynthroidLevothyroxine Sodium | 70 | $6,831 |
| NovologInsulin Aspart | 18 | $6,337 |
| Novolog FlexpenInsulin Aspart | 27 | $5,940 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $5,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $196 | $204,432197 claims |
| Boehringer IngelheimJardiance | $102 | $60,00851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Winston Salem
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.